Delirium: Where do we stand?

被引:6
|
作者
Pae C.-U. [1 ,2 ]
Marks D.M.
Han C.
Patkar A.A.
Masand P.
机构
[1] Department of Psychiatry, The Catholic University of Korea College of Medicine, Seoul 137701, 505 Banpo-Don, Seocho-Gu
[2] Department of Psychiatry and Behavioral Medicine, Duke University Medical Center, Durham, NC 27705
关键词
Haloperidol; Risperidone; Olanzapine; Quetiapine; Aripiprazole;
D O I
10.1007/s11920-008-0040-3
中图分类号
学科分类号
摘要
Clinicians are likely to encounter delirium frequently, particularly in inpatient and intensive care settings. However, delirium is underrecognized and undertreated because of its heterogeneous and fluctuating presentation and due to the limitations in resources and training in contemporary clinical settings. Translation of current knowledge about delirium into clinical practice may improve patient care and benefit public health economics. Hence, this review comprehensively discusses the phenomenology and pathophysiology of delirium and its presenting features, risk factors, differential diagnoses, assessment, prognosis, and treatment with antipsychotics; the goal is to facilitate better prevention, recognition, and treatment of delirium. Available research is reviewed, limitations of the research are discussed, and future directions for further delirium research are identified. Copyright © 2008 by Current Medicine Group LLC.
引用
收藏
页码:240 / 248
页数:8
相关论文
共 50 条
  • [21] WHERE DO WE STAND WITH PPIS
    WELSH, JS
    AMERICAN PHARMACY, 1979, 19 (12): : 12 - 14
  • [22] Hyperfractionation: Where do we stand?
    BeckBornholdt, HP
    Dubben, HH
    LiertzPetersen, C
    Willers, H
    RADIOTHERAPY AND ONCOLOGY, 1997, 43 (01) : 1 - 21
  • [23] Tuberculosis: Where do we stand?
    Becx-Bleumink, M
    Broekmans, JF
    TROPICAL MEDICINE & INTERNATIONAL HEALTH, 1998, 3 (06) : 423 - 424
  • [24] WHERE DO WE STAND ON METRIFICATION
    KIRCHER, KF
    DESIGN NEWS, 1969, 24 (02) : 1 - &
  • [25] Reflections on "Where Do We Stand?"
    Weber, Jennifer L.
    CIVIL WAR HISTORY, 2014, 60 (04) : 404 - 406
  • [26] Biomarkers, Where Do We Stand
    Dixit, Vikash
    Sharma, Payal
    Dhage, Atul Dyandeo
    INDIAN JOURNAL OF PSYCHIATRY, 2015, 57 (05) : S165 - S166
  • [27] Pegasparaginase: where do we stand?
    Zeidan, Amer
    Wang, Eunice S.
    Wetzler, Meir
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2009, 9 (01) : 111 - 119
  • [28] Pharmacovigilance: Where do we stand?
    Peethambaran, K.
    Khanwelkar, C. C.
    JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2010, 4 (03) : 2636 - 2637
  • [29] TUBERCULOSIS - WHERE DO WE STAND
    HOLGUIN, AH
    JOURNAL OF THE AMERICAN COLLEGE OF HEALTH ASSOCIATION, 1968, 17 (02): : 175 - 178
  • [30] QCD - WHERE DO WE STAND
    ALTARELLI, G
    MULTIPARTICLE DYNAMICS 1988, 1988, : 253 - 253